<DOC>
	<DOCNO>NCT00304083</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin , ifosfamide , etoposide , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving combination chemotherapy without radiation therapy surgery may make tumor small reduce amount normal tissue need remove . Giving combination chemotherapy surgery may kill tumor cell remain surgery . PURPOSE : This phase II trial study well combination chemotherapy work treat patient stage III stage IV malignant peripheral nerve sheath tumor .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Stage III Stage IV Malignant Peripheral Nerve Sheath Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine clinical response rate ( complete partial ) patient sporadic neurofibromatosis type 1 ( NF1 ) -associated high-grade stage III IV malignant peripheral nerve sheath tumor ( MPNSTs ) treatment 4 course chemotherapy comprise doxorubicin hydrochloride ifosfamide ( IA ) follow etoposide ifosfamide ( IE ) . Secondary - Evaluate utility fludeoxyglucose F18 positron emission tomography ( ^18FDG-PET ) automate MRI volumetric tumor analysis tool assess response treatment . - Correlate response evaluation 2-dimensional WHO criterion , 1-dimensional RECIST criterion , ^18FDG-PET , volumetric MRI percent necrosis tumor specimens patient undergo surgery local control chemotherapy . - Evaluate response plexiform neurofibroma ( ) ( present ) chemotherapy use WHO criterion automate volumetric MRI analysis . - Evaluate molecular biology sporadic NF1-associated MPNSTs performing detail pathologic analysis tumor sample goal analyze marker identify predict response chemotherapy outcome . - Construct tissue microarray submit tumor sample , use future identify novel target treatment MPNSTs . - Assess serum biomarker identify , predict presence MPNST versus benign plexiform neurofibroma . - Increase knowledge epidemiology clinical presentation NF1-associated MPNSTs . OUTLINE : This multicenter study . Patients stratify accord type malignant peripheral nerve sheath tumor ( MPNST ) ( sporadic MPNST v neurofibromatosis type 1 [ NF1 ] -associated MPNST ) . Patients receive 1 2 treatment regimen depend location MPNST tumor response chemotherapy . - Chemotherapy local control radiotherapy surgery : Patients receive doxorubicin hydrochloride ifosfamide ( IA ) chemotherapy comprise doxorubicin hydrochloride IV 15 minute day 1 2 ifosfamide IV 1 hour day 1-5 . Treatment repeat every 21 day 2 course absence unacceptable toxicity . Patients receive etoposide ifosfamide ( IE ) chemotherapy comprise etoposide IV 1 hour ifosfamide IV 1 hour day 1-5 . Treatment repeat every 21 day 2 course absence disease progression unacceptable toxicity . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) chemotherapy course begin day 6 7 continue blood count recover pegfilgrastim SC day 6 7 . After recovery chemotherapy , patient undergo radiotherapy receive 2 course IE radiotherapy follow 2 course IA completion radiotherapy . Some patient may undergo surgery . - Chemotherapy local control surgery : Patients receive 2 course IA follow 2 course IE . After recovery chemotherapy , patient undergo surgery . After recovery surgery , patient receive 2 course IA follow 2 course IE absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 74 patient accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neurofibromatoses</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Neurofibromatosis 1</mesh_term>
	<mesh_term>Nerve Sheath Neoplasms</mesh_term>
	<mesh_term>Neurilemmoma</mesh_term>
	<mesh_term>Neurofibrosarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose sporadic neurofibromatosis type 1 ( NF1 ) associate highgrade malignant peripheral nerve sheath tumor ( MPNSTs ) Stage III stage IV ( metastatic ) disease Measurable disease , define least 1 tumor measurable 2 dimension CT scan MRI PATIENT CHARACTERISTICS : Ejection fraction normal echocardiogram MUGA Serum creatinine normal age OR creatinine clearance &gt; 60 mL/min SGPT &lt; 5 time upper limit normal ( ULN ) Bilirubin &lt; 2.5 time ULN Absolute neutrophil count ≥ 1,500/mm^3* Hemoglobin ≥ 9.0 g/dL* Platelet count ≥ 100,000/mm^3* ECOG performance status 02 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month completion study treatment NOTE : * Unsupported PRIOR CONCURRENT THERAPY : No prior chemotherapy MPNST Prior surgical resection MPNST allow provide residual recurrent measurable disease present Recovered toxic effect prior therapy At least 3 week since prior chemotherapy biologic therapy treatment plexiform neurofibroma , optical pathway tumor , NF1associated tumor ( patient NF1 ) At least 6 week since prior radiotherapy treatment plexiform neurofibroma , optical pathway tumor , NF1associated tumor ( patient NF1 ) At least 4 week since prior radiotherapy area involve MPNST No concurrent growth factor ( e.g. , sargramostim [ GMCSF ] interleukin11 ) Concurrent epoetin alfa allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>adult neurofibrosarcoma</keyword>
	<keyword>childhood neurofibrosarcoma</keyword>
	<keyword>metastatic childhood soft tissue sarcoma</keyword>
	<keyword>nonmetastatic childhood soft tissue sarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
	<keyword>neurofibromatosis type 1</keyword>
</DOC>